Key Highlights
- Percy Carter, MBA, Ph.D., appointed to Cellarity’s Board of Directors.
- Carter currently serves as Chief Scientific Officer at Blueprint Medicines.
- Carter brings extensive leadership experience from Janssen Pharmaceuticals and Bristol Myers Squibb.
- Cellarity’s platform leverages AI to decode cell behavior and uncover novel drug candidates.
- Company focuses on hematology, immunology, and metabolic dysfunction-associated steatohepatitis (MASH).
Source: Business Wire
Notable Quotes
- “I look forward to his insights in leveraging the reproducibility of our platform across disease areas and shaping a pipeline of medicines that matter.” — Fabrice Chouraqui, Pharm.D., CEO at Cellarity
- “I am delighted to join the Board of Directors at Cellarity as the company sets out to challenge the status quo of drug discovery with its unique platform.” — Percy Carter, MBA, Ph.D., Chief Scientific Officer at Blueprint Medicines
- “We are thrilled to add Percy to our experienced Board of Directors to help Cellarity’s management team re-write the rules of drug discovery.” — Stephen Berenson, Chairman of the Board of Directors at Cellarity
SoHC's Take
The appointment of Dr. Percy Carter to Cellarity’s Board of Directors marks a significant step forward for the company. His extensive background in drug discovery and platform development, particularly at prestigious organizations like Blueprint Medicines, Janssen Pharmaceuticals, and Bristol Myers Squibb, positions him as a valuable asset to Cellarity. His expertise will be crucial in advancing Cellarity’s innovative platform, which utilizes AI to decode cellular behavior and uncover novel drug candidates. This strategic addition aligns with Cellarity’s mission to revolutionize drug discovery, promising to drive forward impactful medical breakthroughs in hematology, immunology, and metabolic disorders.
